Rong Y, Darnell AM, Sapp KM, Heiden MGV, Spencer SL. Cells use multiple mechanisms for cell-cycle arrest upon withdrawal of individual amino acids. Cell reports. 2023;42(12):113539. doi:10.1016/j.celrep.2023.113539Google ScholarPubMedDOI
Giltnane JM, Hutchinson KE, Stricker TP, et al. Genomic profiling of ER breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9(402). doi:10.1126/scitranslmed.aai7993Google ScholarPubMedDOI
Shee K, Yang W, Hinds JW, et al. Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018;215(3):895-910. doi:10.1084/jem.20171818Google ScholarPubMedDOI
Gopal RK, Calvo SE, Shih AR, et al. Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma. Proc Natl Acad Sci U S A. 2018;115(27):E6283-E6290. doi:10.1073/pnas.1711888115Google ScholarPubMedDOI
Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-62. doi:10.1038/nature04304Google ScholarPubMedDOI
Gong Y, Zack TI, Morris LGT, et al. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet. 2014;46(6):588-94. doi:10.1038/ng.2981Google ScholarPubMedDOI
Lee Y, Dominy JE, Choi YJ, et al. Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression. Nature. 2014;510(7506):547-51. doi:10.1038/nature13267Google ScholarPubMedDOI
Kennedy AL, Vallurupalli M, Chen L, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015;6(30):30178-93. doi:10.18632/oncotarget.4903Google ScholarPubMedDOI